A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Trial Profile

A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Oct 2017

At a glance

  • Drugs Gilteritinib (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Acronyms CHRYSALIS
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 12 Oct 2017 Planned End Date changed from 1 Dec 2017 to 1 Jan 2018.
    • 25 Jun 2017 Results of this (patients) and other study (healthy volunteers) assessing drug-drug interaction potential of Gilteritinib, presented at the 22nd Congress of the European Haematology Association.
    • 25 Jun 2017 Results (n=152) presented at the 22nd Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top